SIRT1 and metabolic dysfunction-associated steatotic liver disease: Our study revealed that ATL III treatment effectively ameliorated NAFLD by regulating AdipoR1 mediated AMPK-SIRT1 signaling pathway, suggesting that ATL III has therapeutic potential for the treatment of NAFLD.